Zai Lab could net $761 million from Hong Kong listing

Nasdaq-listed Zai Lab raised about $766 million from its Hong Kong listing. The company priced its secondary listing in Hong Kong to be approximately $72.50 per share, under its previously set maximum price target of $83.60.

The Chinese biotech could net more than $761 million from the offering, which the company plans to use to fund its R&D projects and further commercialize its two core products: Zejula, a drug for ovarian cancer, and Optune, a medical device treatment for glioblastoma multiforme.